Radius Health (RDUS) Posts Wider Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Radius Health Reports First Quarter 2016 Financial and Operating Results
May 5, 2016 6:30 AM EDTRadius submitted an NDA to the US FDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis and reduction of fracture risk.
 An MAA for abaloparatide-SC is currently under regulatory review by the European Medicines Agency and we expect a CHMP scientific opinion in 2016.
Cash, cash equivalents and marketable securities totaled $439.8 million as of March 31, 2016.               Â
WALTHAM, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS), a science-driven biopharmaceutical company that is committed to developing... More
